TEVA PHARMACEUTICAL INDUSTRIES LTD

Pharmaceutical Preparations·TEL AVIV·FY end 12/31·CIK 818686

CEO Pay Ratio

257:1

Richard Francis

CEO Total Comp

$19.2M

Richard Francis

Median Employee

$74,725

Revenue

$1.5B

FY 2025

Net Income

$1.4B

FY 2025

Free Cash Flow

—

FY 2025

Net Margin

94.0%

Insider Net (180d)

0 buys / 0 sales

CEO Pay Accountability

CEO comp as % of net income

1.36%

For every $1,000 of profit, $13.59 flows to the CEO.

CEO comp as % of buybacks

—

No buyback data for the most recent fiscal year.

5-year history · USD

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	Trend
Revenue	$1.5B	$16.5B	$15.8B	$14.9B	$15.9B
Gross Profit	$8.9B	$8.1B	$7.6B	$7.0B	$7.6B
Operating Income	$2.2B	-$303.0M	$344.0M	-$2.1B	$1.7B
Net Income	$1.4B	-$1.6B	$70.0M	-$2.4B	$417.0M
Operating CF	$1.6B	$1.2B	$1.4B	$1.6B	$798.0M
Capex	—	—	—	$548.0M	$562.0M
Free Cash Flow	—	—	—	$1.0B	$236.0M
Buybacks	—	—	—	—	—	—
Dividends	—	—	—	—	—	—

Gross Margin	595.9%	48.7%	48.2%	46.7%	47.8%
Operating Margin	143.8%	-1.8%	2.2%	-14.1%	10.8%
Net Margin	94.0%	-9.9%	0.4%	-15.8%	2.6%
FCF Margin	—	—	—	7.0%	1.5%
R&D / Revenue	—	—	—	0.7%	—	—
Effective Tax	—	—	—	—	—	—
Debt / Equity	—	—	—	—	—	—
Buybacks / FCF	—	—	—	—	—	—

FY 2025

Executive	Salary	Stock	Options	Bonus / Inc.	Other	Total
Richard FrancisPresident and Chief Executive Officer	$1.7M	$12.0M	—	$4.8M	$641.3K	$19.2M
Evan LippmanExecutive Vice President, Business Development	$496.9K	$4.9M	—	$1.8M	$50.3K	$7.2M
Eli KalifExecutive Vice President, Chief Financial Officer	$1.0M	$3.8M	—	$1.8M	$360.7K	$7.0M
Dr. Eric HughesExecutive Vice President, Global R&D and Chief Medical Officer	$829.2K	$3.7M	—	$1.6M	$149.9K	$6.3M
Christine FoxExecutive Vice President, US Commercial	$849.2K	$3.4M	—	$1.6M	$38.3K	$5.9M